8-K
filed March 9, 2023, 6:59 PM ET
ticker HSDT
CIK 0001610853
earnings
confidence high
sentiment neutral
materiality 0.55
Helius Medical Q4 revenue $282K, FY22 rev $787K (+51% YoY); net loss narrows
Solana Co
- Q4 revenue $282K (+9% YoY, +44% sequential); FY22 revenue $787K (+51% YoY).
- Net loss Q4 $4.9M ($0.17/sh) vs $4.1M ($1.31/sh) in Q4 2021; FY22 net loss $14.1M ($1.04/sh).
- Cash $14.5M at Dec 31, 2022, no debt; Q4 cash burn $2.1M vs prior quarterly avg $4.1M.
- Expects 2023 revenue to exceed 2022 and increase during year; reimbursement needed for full potential.
- Health Canada authorized PoNS for gait deficit due to mild/moderate stroke; launched UpScript e-commerce site.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Solana Co reported Q4 2022 results: revenue $282 thousand, net income $4.9 million, EPS $0.17.
- Period
- Q4 2022
- Revenue
- $282 thousand
- Net income
- $4.9 million
- EPS
- $0.17
- Result
- reported results
Exact text from the filing
Total revenue for the fourth quarter of 2022 was $282 thousand, an increase of 9% compared to $258 thousand in the fourth quarter of 2021 and was comprised primarily of product sales in both periods. Cost of revenues was $150 thousand for the three months ended December 31, 2022, compared to $129 thousand for the comparable period in 2021, primarily due to increased revenues. Gross profit for the fourth quarter of 2022 was $132 thousand, compared to gross profit of $129 thousand in the fourth quarter of 2021. Operating expenses for the fourth quarter of 2022 decreased to $2.8 million, compared to $4.2 million in the fourth quarter of 2021. The decrease was primarily the result of lower product development and clinical trial activities following the U.S. commercial launch of PoNS. Operating loss for the fourth quarter of 2022 decreased $1.4 million to a loss of $2.7 million, compared to an operating loss of $4.1 million in the fourth quarter of 2021. Net loss was $4.9 million for the fo
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Solana Co updated its 2023 guidance (initiated).
- Period
- 2023
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
2023 Guidance The Company currently expects 2023 revenues to exceed prior year levels and increase throughout the year, though we may experience quarterly fluctuations as we make refinements to our U.S. commercial roll-out of PoNS.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.9
Solana Co reported Full Year 2022 results: revenue $787 thousand, net income $14.1 million, EPS $1.04.
- Period
- Full Year 2022
- Revenue
- $787 thousand
- Net income
- $14.1 million
- EPS
- $1.04
- Result
- reported results
Exact text from the filing
Total revenue for the full year 2022 was $787 thousand, compared to $522 thousand for the full year 2021, reflecting the U.S. commercial launch of PoNS for MS in April 2022, partially offset by a decrease in product sales in Canada, mostly attributable to lower Canadian to U.S. dollar translation rates during 2022. Cost of revenue for the full year 2022 increased $165 thousand to $463 thousand, compared to cost of revenue of $298 thousand for the full year 2021, primarily attributable to overhead costs, including salaries and benefits of employees involved in management of the supply chain, and inventory-related cost of sales due to higher sales volume. Gross profit for the full year 2022 was $324 thousand, compared to gross profit of $224 thousand for the full year 2021. Operating expenses for the full year 2022 decreased $2.5 million to $15.8 million, compared to $18.4 million for the full year 2021, due primarily to a $2.0 million decrease in stock-based compensation expense and a d
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.